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Background/aim: The known pathogenesis of diabetes mellitus (DM) in acromegaly is mainly based on growth hormone (GH) and
insulin-like growth factor-1 (IGF-1) excess. Fatty acid-binding protein 4 (FABP-4), a novel adipokine, is found to induce insulin
resistance and type 2 DM. We aimed to investigate the possible effect of FABP-4 on glucose metabolism in patients with acromegaly.
Materials and methods: This case-control study included 28 patients newly diagnosed with acromegaly and 57 healthy volunteers.
The patients with acromegaly were classified according to their glycemic status as with DM, prediabetes, and normal glucose tolerance.
Anthropometric measurements, laboratory test results, and FABP-4 levels of the subjects were evaluated.
Results: Although no difference was observed in FABP-4 levels between acromegaly and control groups, the FABP-4 level was higher in
the patients with acromegaly having DM compared to the patients with acromegaly having prediabetes and NGT, and the control group
(p = 0.004, p = 0.001, p = 0.004, respectively). Logistic regression analysis suggested that the FABP-4 is an independent predictor of DM
in acromegaly (β = 7.382, OR = 38.96, 95% CI: 1.52-5.76, p = 0.018).
Conclusion: The FABP-4 may be a helpful predictor of acromegaly-associated DM.
Key words: Acromegaly, adipokin, FABP-4, diabetes mellitus

1. Introduction
Acromegaly develops as a result of excessive growth
hormone (GH) and insulin-like growth factor-1 (IGF-1)
release and is caused mostly by a pituitary adenoma. The
estimated incidence of this rare condition was reported as
0.2–1.1 cases/100000 people/year [1]. Diabetes mellitus
(DM), impaired glucose metabolism, insulin resistance,
hypertension, and cardiovascular diseases are common in
acromegaly and contribute to increased risk of mortality
[2,3]. Impaired glucose metabolism is one of the most
common metabolic morbidities in acromegaly, and the
reported prevalence ranges from 15% to 50% depending
on the genetic and ethnic factors of the patients [2]. DM
frequency in acromegaly has been indicated in a wide
range of 16% to 56% in various studies from different
populations [4–6].
Despite the impacts of genetic, familial, and
environmental risk factors on type 2 DM occurrence,
it is known that DM in acromegaly develops as a result
of the effects of GH and IGF-1 excess on the pancreatic

β-cell function, insulin sensitivity, and gluconeogenesis
[7]. Recent studies have revealed that altered adipokine
variety and quantity in adipose tissue might contribute to
the pathogenesis of insulin resistance and DM in patients
with acromegaly [8].
Fatty acid-binding protein-4 (FABP-4) is a novel
adipokine, which is expressed in adipocytes and plays
a part in the initiative mechanism of insulin resistance
and type 2 DM via suppressing PPAR gamma [9]. FABP4 induced PPAR gamma inhibition particularly acts as
a role in lipid-mediated inflammation and oxidation
processes [9]. With the initiation of this inflammatory
process, glycolysis and glucose oxidation begin to be
inhibited and the glucose uptake of peripheral tissues,
mainly the liver and muscles, reduces [9]. Thus, increased
FABP-4 leads to the development of insulin resistance as
a consequence of defective insulin secretion. Previous
studies have established that FABP-4 was linked to type
2 DM, gestational DM, and metabolic syndrome [10–12].
Although adequate data in the linkage between FABP-4

* Correspondence: semahepsen@gmail.com

2592

This work is licensed under a Creative Commons Attribution 4.0 International License.

HEPŞEN et al. / Turk J Med Sci
level and type 2 DM have been presented in the literature,
as far as we know, the association between FABP-4 and
DM in acromegaly was not investigated before.
Depending on the hypothesis that FABP-4 was closely
relevant to glucose metabolism impairment, we aimed
to evaluate FABP-4 levels in patients with acromegaly,
especially patients with acromegaly-associated DM.
2. Material and methods
2.1. Study design
This study was designed as a case-control study. The Ethics
Committee of our institute approved this study regarding
the principles of the Helsinki Declaration (Clinical
Research Ethics Committee University of Health Sciences,
Diskapi Yildirim Beyazit Training and Research Hospital,
Approval number: 71/08). Written informed consent was
taken before being participated in the study.
2.2. Patients and laboratory tests
Between December 2017 and December 2019, a total
of 28 patients were diagnosed with acromegaly in the
endocrinology and metabolism department. Acromegaly
diagnosis was based on the Endocrine Society Clinical
Practice Guideline [13]. Serum IGF-1 level was measured
in patients who had typical acromegaly physical features or
had acromegaly associated conditions such as type 2 DM,
hypertension, and sleep apnea syndrome in the absence
of typical acral and facial stigmata. Anthropometric and
laboratory data of the patients were examined at the time
of diagnosis, before being undergone a pituitary surgery or
being started medical treatment with somatostatin analogs.
The control group was composed of 57 randomly selected
healthy subjects who were admitted to our hospital for
routine controls and agreed to participate in our study.
Foreknown comorbidities of the patients such as
hypertension, DM, and atherosclerotic cardiovascular
diseases were questioned. DM of the patients with
acromegaly was categorized as newly diagnosed or
previously known. Diabetic patients were also questioned
for their family history of DM. DM and prediabetes
diagnosis criteria were based on the American Diabetes
Association (ADA) guidelines. DM criteria were based
upon either fasting plasma glucose (FPG) ≥ 126 mg/dL or
2-h post-prandial glucose (PG) ≥ 200 mg/dL during oral
glucose tolerance test (OGTT) or glycated hemoglobin
(HbA1c) ≥ 6.5% (48 mmol/mol) [14]. Prediabetes is
defined as the presence of either FPG 100–125 mg/dL
or 2-h PG during 75 g OGTT 140–199 mg/dL or HbA1c
5.7%–6.4% (39–46 mmol/mol) [14]. The homeostasis
model assessment formula for insulin resistance (HOMAIR) was evaluated in patients with normal glucose tolerance
(NGT) and prediabetes [15]. The patients with acromegaly
were divided into subgroups according to their glucose
metabolism status in terms of being with DM, prediabetes,
and normal glucose tolerance (NGT).

Anthropometric measurements of the participants
such as weight, height, waist, and hip circumference were
examined. The body mass index (BMI) was calculated by
dividing the weight by the square of the height (kg/m2).
WHO classification was used to determine obesity [16].
Blood pressure was measured from the right arm using a
mercury sphygmomanometer with the subject seated after
a 10- min rest.
Peripheral blood samples were collected between
8:00 and 10:00 am after at least 8 h of overnight fasting.
Serum samples for the FABP-4 analysis were reserved for
2 h at room temperature and then centrifuged for 20 min
at approximately 1000×g. All serum samples were stored
at −80 °C until the day of analysis. A sandwich enzyme
immunoassay kit was used to determine in vitro quantitative
measurement of FABP-4 (Cloud-Clone Corp, Houston,
TX, USA). FPG was determined through the enzymatic
UV test (Beckman Coulter AU, USA). HbA1c level was
determined by the ion-exchange high-performance liquid
chromatography (HPLC) method (Tosoh Bioscience, G8,
USA). Serum lipid parameters were examined using the
enzymatic colorimetric method (Beckman Coulter AU,
USA). Thyroid-stimulating hormone (TSH), insulin, GH,
and IGF-1 levels were analyzed via the chemiluminescence
immunoassay method (Beckman Coulter, Access 2, USA).
HOMA-IR was calculated according to the following
formula: FPG (mg/dL) x fasting insulin (mU/ml)/405.
Normal ranges of GH and IGF-1 were as follows: 0.05–8
ng/mL, 42–214 ng/mL, respectively.
Echocardiographic examination was performed using
a standard ultrasound system (Philips EPİQ 5, Philips
Healthcare, USA). Left ventricle ejection fraction (EF)
was evaluated based on the modified biplane Simpson’s
method. Left ventricular hypertrophy (LVH) was defined
as an increase in the size of myocardial fibers of the left
ventricle [17].
2.3. Statistical analysis
Statistical analyses were performed using the SPSS
software version 21 (Chicago, IL). The variables were
investigated by means of visual (histograms, probability
plots) and analytic methods (Kolmogorov–Smirnov/
Shapiro–Wilk’s test) to determine whether they are
normally distributed or not. While the Student’s t-test was
used to compare age, waist circumference, creatinine, total
cholesterol, high-density lipoprotein cholesterol (HDL-C),
and low-density lipoprotein cholesterol (LDL-C) levels,
the Mann–Whitney U test was performed to compare
sex, BMI, hip circumference, systolic and diastolic blood
pressure, HOMA-IR, FPG, HbA1c, GH, IGF-1, TSH,
ALT, and triglyceride levels. Descriptive analyses were
presented using means and standard deviations for
normally distributed variables, whereas medians and
interquartile ranges (IQR) between 25 and 75 percentiles
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for nonnormally distributed variables. A p-value less than
0.05 was considered to show a statistically significant
difference. The Kruskal-Wallis tests were conducted to
compare FABP-4 levels and other laboratory parameters
among the groups, which were composed according to
their glucose metabolism and insulin resistance status.
The Mann–Whitney U test was performed to examine
the significance of pairwise differences using Bonferroni
correction to adjust for multiple comparisons. Overall,
a 5% type-1 error level was used to infer statistical
significance. While investigating the associations between
FABP-4 level and other variables, correlation coefficients
and their significance were calculated using the Spearman
test. A logistic regression analysis was used to identify the
independent predictors of DM in acromegaly. Hosmer–
Lemeshow goodness of fit statistics was used to assess
model fit. A 5% type-I error level was used to infer
statistical significance.
3. Results
Twenty-eight patients newly diagnosed with acromegaly
and 57 controls were included in the study. The age and
sex distribution of the controls were similar to the patients
with acromegaly (p > 0.05). The patients with acromegaly
had higher BMI and waist circumference than controls
(p = 0.014, p = 0.02 respectively). All of the patients
with acromegaly had a pituitary adenoma. Five (17.8%)
patients had a microadenoma, while 23 (82.2%) had a
macroadenoma. 26 (92.8%) patients underwent a transnasal
transsphenoidal pituitary surgery, and 2 (7.2%) patients
were started on somatostatin analog treatment as the firstline therapy. A total of 46.4% of patients with acromegaly
had hypertension. Systolic and diastolic blood pressure
values were higher in the patients with acromegaly than in
the control group (p = 0.001 and p < 0.001, respectively).
Nine of 28 patients with acromegaly (32.1%) had DM
and 9 of 28 (32.1%) had prediabetes. Only one patient
with acromegaly had a family history of DM. While 5 of 9
diabetic patients were diagnosed with DM and acromegaly
concurrently, 4 patients had a previously diagnosed DM.
The initial treatment was a pituitary surgery for all patients
with acromegaly with DM and prediabetes, and glucose
metabolism was improved in all of these patients after the
surgery. Five of 28 patients with acromegaly (17.8%) had
insulin resistance. FPG, HbA1c levels, HOMA-IR, GH, and
IGF-1 were higher in the patients with acromegaly than that
of controls (p < 0.0001 for each). Baseline characteristics
and laboratory test results belonging to the groups are
presented in Table 1.
The difference in FABP-4 levels between all patients
with acromegaly and the control group was not statistically
significant (p = 0.286). A statistically significant difference
was observed in FABP-4 levels among the groups when
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compared the patients with acromegaly having DM and
the controls, with acromegaly having DM and prediabetes,
with acromegaly having DM and NGT, respectively
(p = 0.014, p = 0.004, p = 0.001) (Figure). Despite the
difference was not statistically significant, the patients with
acromegaly having DM had higher levels of GH compared
to the patients with acromegaly having prediabetes and
NGT (p = 0.077, p = 133, respectively). Baseline data,
laboratory parameters, and FABP-4 levels of the groups
are presented in Table 2.
No difference was observed in FABP-4 levels compared
to the patients with and without insulin resistance (p =
0.380), obesity (p = 0.223), hypertension (p = 0.995), and
LVH (p = 0.553).
We established that the FABP-4 is positively correlated
to FPG, HbA1c, and GH levels in the acromegaly group
(r = 0.548; p = 0.003, r = 0.478; p = 0.012, r = 0.418; p
= 0.027, respectively). However, any association is not
determined between FABP4 levels and age, sex, BMI,
FPG, HbA1c, GH, and IGF-1 in the whole study group
including both patients and controls. Logistic regression
analysis was calculated to detect independent predictors
of DM in acromegaly based on the variables, including
age, sex, FABP-4, IGF-1, and GH levels and was presented
in Table 3. Logistic regression analysis suggested that the
FABP-4 level is an independent predictor of DM but not
the other variables (β = 7.382, OR = 38.96, 95% CI: 1.525.76, p = 0.018).
4. Discussion
The results of the present study demonstrated that FABP4 levels were higher in the patients with acromegaly
having DM compared to the patients without DM and the
controls. Logistic regression analysis also suggested that
the FABP-4 level is an independent predictor of DM in
acromegaly but not age, sex, IGF-1, and GH.
Patients with acromegaly have a higher risk of glucose
metabolism disorders compared to the general population
[5]. While DM prevalence in the patients with acromegaly
varies in the range of 16% to 56% among different study
populations, the prevalence of impaired fasting glucose
and glucose tolerance have been reported as 8.9% to 19%
and 15% to 31.6%, respectively [5,6,18]. Similar to the
literature, the frequencies were found out 32.1% for DM
and 32.1% for prediabetes in the present study.
GH physiologically affects glucose metabolism and leads
to hepatic gluconeogenesis, lipolysis, and glycogenolysis.
Increased glucose and free fatty acid production induce
insulin resistance in the liver and peripheral tissues [19].
Besides the direct effects of GH contrary to insulin action,
GH conduces to improve insulin activity via stimulating
IGF-1 [7]. However, the insulin agonistic effect of IGF1 is inadequate to overcome the direct impact of GH on
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Table 1. The comparisons of demographic data, anthropometric measurements, and laboratory test results of the
patients with acromegaly and controls.
Patients with acromegaly

Controls

p value

Demographic and anthropometric data
Number, n

28

57

Age, years

48.2 ± 8.8

50.3 ± 10.3

.319

Female, n (%)

18 (64.3)

40 (70.2)

.586

BMI, kg/m2

30.4 (27.6–35.6)

28.4 (25–31.8)

.014

Waist circumference, cm

98.8 ± 15.3

89.3 ± 9.7

.02

Hip circumference, cm

103 (100–120)

105 (100–110)

.446

Systolic BP, mm/Hg

120 (120–130)

120 (110–120)

.001

Diastolic BP, mm/Hg

75 (70–80)

70 (60–70)

< .0001

Hypertension, n (%)

13 (46.4)

0 (0)

-

Diabetes mellitus, n (%)

9 (32.1)

0 (0)

-

Prediabetes, n (%)

9 (32.1)

0 (0)

-

Insulin resistance, n (%)

5 (17.8)

0 (0)

-

Obesity, n (%)

15 (53.6)

21 (36.8)

.145

LVH, n (%)

8 (28.7)

0 (0)

.014

EF, %

65 (60–65)

65 (60–65)

.888

FPG, mg/dL

103 (91–138)

83 (80–90)

< .0001

HbA1c, %

6.1 (5.7–7)

5.6 (5.4–5.7)

< .0001

HOMA–IR

3.7 (1.9–6.4)

1.15 (0.9–1.6)

< .0001

Total cholesterol, mg/dl

187 ± 19

188 ± 42

.889

Triglyceride, mg/dl

128 (109–189)

99 (68–138)

.005

HDL-C, mg/dL

43 ± 8

50 ±10

.002

LDL-C, mg/dL

129 ± 19

132 ± 35

.669

Creatinine, mg/dL

0.79 ± 0.2

0.83 ± 0.8

.076

ALT, mg/dL

15 (14–18)

18 (15–23)

.088

TSH, µIU/mL

1 (0.6–1.8)

1.3 (1–2)

.084

IGF-1, ng/mL

536 (453–629)

169 (133–194)

< .0001

GH, ng/mL

10.2 (3.4–35)

1.9 (1.45–2.3)

< .0001

FABP-4, ng/mL

1.52 (1.42–1.81)

1.61 (1.49–1.87)

.286

Laboratory test results

Categorical data were demonstrated with numbers and percentages (%). Normally distributed variables were presented
as means (standard deviations) and nonnormally distributed variables were presented as medians (interquartile range:
25–75).
Abbreviations: BMI: body mass index, BP: blood pressure, LVH: left ventricle hypertrophy, EF: ejection fraction,
FPG: fasting plasma glucose, HDL-C: high-density lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol,
ALT: alanine aminotransferase, TSH: thyroid-stimulating hormone, IGF-1: insulin-like growth factor-1, GH: growth
hormone, FABP-4: fatty acid-binding protein 4.

glucose metabolism. Impaired glucose metabolism and
DM develop as a result of decreased insulin sensitivity and
secretion [20].
Adipose tissue, one of the targets of GH excess, plays
a significant role in glucose metabolism impairment via

lipolytic activity [7]. Previous studies have established
that GH increases adipose tissue hormone-sensitive lipase
activity and leads to FFA release to the peripheral tissues
[7]. This was assumed that adipose tissue dysfunction is
more important than the amount of the accumulated
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2.50

FABP-4 ng/mL

2.25

2.00

1.75

1.50

1.25
Controls

Acromegaly with
diabetes mellitus

Acromegaly with
prediabetes

Acromegaly with
NGT

Glucose metabolism statuses

Figure. Estimated FABP4 levels according to glucose metabolism statuses. The p values
were as follows among groups: p = 0.004 (acromegaly with diabetes vs. acromegaly with
prediabetes), p = 0.001 (acromegaly with diabetes vs. acromegaly with normal glucose
tolerance), p = 0.014 (acromegaly with diabetes vs. controls).
Table 2. The comparisons of baseline characteristics and laboratory parameters among acromegaly groups in terms of their glucose
metabolism statuses and controls
p value
DM vs
controls

p value
DM vs
prediabetes

p value
DM vs
NGT

40/17

0.385

1.00

0.4

28.4 (25–31.8)

0.318

0.149

0.963

1.47 (1.34–1.58)

1.6 (1.49–1.87)

0.014

0.004

0.001

90 (82–95)

83 (80–90)

<0.001

<0.001

<0.001

6.1 (6–6.3)

5.6 (5.6–5.7)

5.6 (5.4–5.7)

<0.001

<0.001

<0.001

545 (442–787)

536 (446–602)

169 (133–194)

<.0001

0.077

0.133

8 (3–18.3)

5.5 (1.7–24.5)

1.9 (1.45–2.3)

<.0001

0.436

0.842

Acromegaly
with DM

Acromegaly
with prediabetes

Acromegaly
with NGT

Controls

Number, n (%)

9 (32.1)

9 (32.1)

10 (35.8)

57 (100)

Female/male

5/4

5/4

8/2

BMI, kg/m2

29.2 (28–31.7)

36.8 (28–42)

30.5 (25.6–33.6)

FABP-4, ng/mL 2 (1.71–2.23)

1.47 (1.42–1.55)

FPG, mg/dL

175(130–189)

104 (99–106)

HbA1c, %

9.8 (7.5–12.4)

IGF-1, ng/mL

507 (421–632)

GH, ng/mL

21 (9.4–40)

Nonnormally distributed variables were presented as medians (interquartile range: 25–75).
Abbreviations: FABP-4: fatty acid-binding protein 4, DM: diabetes mellitus, NGT: normal glucose tolerance, BMI: body mass index,
FPG: fasting plasma glucose, IGF-1: insulin-like growth factor-1, GH: growth hormone.

visceral fat in the pathogenesis of insulin resistance and
DM in acromegaly [19]. Furthermore, the adipose tissue
dysfunction changes the variety and quantity of adipokines
and a change in adipokine distribution causes a more
inflamed fat that is suspected in insulin resistance and DM
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[8]. These novel studies bring to mind that the occurrence
of DM in acromegaly may not be solely mediated with GH.
The FABP-4 is a member of the calycin protein
superfamily and is expressed in adipocytes and
macrophages [9]. FABP-4 expression particularly enhances
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Table 3. Binary logistic regression analysis results showing the predictive values
of the parameters for the presence of diabetes mellitus.
B

SE

OR

95% CI

p value

Age

0.186

0.117

0.111

0.95–1.51

0.953

Sex

0.079

1.33

1.082

0.1–14.7

0.953

GH

0.102

0.058

1.107

0.98–1.24

0.077

IGF-1

0.005

0.004

1.005

0.99–1.01

0.243

FABP-4

7.382

3.11

38.96

1.52–5.76

0.018

Abbreviations: SE: standard error, OR: odds ratio, CI: confidence interval,
IGF-1: insulin-like growth factor-1, GH: growth hormone, FABP-4: fatty acidbinding protein 4.

when the adipocytes were differentiating [9]. FABP-4 acts
a crucial role in glucose and lipid homeostasis through
mediating inflammation and oxidation. The FABP-4
affects glucose metabolism via negatively regulating PPAR
gamma activity, which promotes adipocyte differentiation,
proliferation, and insulin sensitivity of adipocytes [21,22].
With the activation of this inflammatory process, the
inhibition of glucose oxidation and glycolysis begins, and
glucose uptake of peripheral tissues such as the liver and
muscles decreases [9]. FABP-4 also contributes to insulin
resistance by accumulating short-chain-free fatty acids.
Previous studies have established that FABP-4 is associated
with type 2 DM, gestational DM, cardiovascular diseases,
obesity, and metabolic syndrome [23–25]. A 10-year study
including the Chinese population has demonstrated that
the FABP-4 level is a predictor of DM development [26].
Another study including the U.S. male participants have
determined that the FABP-4 level is associated with the
increased risk of DM [12]. In this study, there was no
difference in FABP-4 levels among the groups with and
without obesity, hypertension, and LVH. According to the
results of the present study, the FABP-4 level was found
to be higher in patients with acromegaly and DM. Only
one patient had a family history of DM in our diabetic
acromegaly group. DM was diagnosed concurrently with
acromegaly in most of the patients. Glucose metabolism
of all patients with DM and prediabetes was improved
after the surgery as well. All these findings taken together
indicate that the diagnosis of DM of our patients with
acromegaly was related to acromegaly rather than
concomitant type 2 DM to acromegaly. This is noteworthy
to point that the correlation analysis of this study showed a
linear association between FABP-4 level and HbA1c in the
acromegaly group. The patients with acromegaly having
DM have also a higher HbA1c than the other 3 groups.
With respect to these results, it can be commentated that
a higher FABP-4 level may indicate poorly controlled DM.

However, there was no difference between our patients
with and without insulin resistance. The small sample size
belonging to subgroups may be the explanation for this
discrepancy.
This was also shown that GH modulates the expression
of gene-related adipocyte differentiation and inhibits the
expression of various molecules including adiponectin and
PPAR gamma [27]. In the present study, the patients with
acromegaly having DM had higher GH levels compared to
the patients with acromegaly having prediabetes and NGT,
and FABP-4 was found positively correlated to GH. It may
be hypothesized that GH may also be mediating FABP4 expression because they both induce PPAR gamma
inhibition.
Various studies have indicated that higher levels of
IGF-1, older age, and family history of DM were related to
DM in acromegaly [5,28]. A study evaluating the French
acromegaly population has suggested that age, BMI, and
hypertension were predictors of DM presence, but not
IGF-1 and GH [6]. IGF-1 level at the diagnosis time and
the presence of hypertension were found to be associated
with DM development in another study including Mexican
patients with acromegaly [29]. Our study revealed that the
FABP-4 is an independent predictor of DM.
That having a small size of samples in groups is a
limitation of our study. However, the number of patients
may be acceptable considering the rarity of acromegaly.
We also included all patients newly diagnosed with
acromegaly in our institute within the defined period to
eliminate any bias. A point that needs to be clarified is that
the obesity rate of control subjects is close to the rate of the
patients with acromegaly. However, controls were selected
randomly and we did not determine any relationship
between obesity and FABP-4 levels.
In conclusion, the FABP-4 level was determined to be
higher in the patients with acromegaly having DM and it
may be a helpful predictor of acromegaly-associated DM.
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